ArticleFrontiers in bioengineering and biotechnology2022
Small intestinal submucosa-derived extracellular matrix as a heterotopic scaffold for cardiovascular applications.
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Porcine Small Intestinal Submucosa Extracellular Matrix: A Meta-Analysis of Composition, Processing Techniques, and Biomedical Applications.International journal of molecular sciences · 2025Pooled it
- Benchmarking of Decellularization Protocols for Small Intestinal Submucosa: Defining the Gold Standard for Functional Tissue Engineering.Materials (Basel, Switzerland) · 2026Article
- Effects of Bovine Milk-Derived Extracellular Vesicles on a 3D Intestinal Stromal Compartment.Cells · 2026Article
- Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) and Small Intestinal Submucosa (SIS) Hydrogel Composite Can Meliorate TNBS-Induced Experimental Colitis Through Regulating Inhibiting Macrophage Polarization Toward the M1 Phenotype.Mediators of inflammation · 2026Article
- New frontiers in porcine atrioventricular node decellularization: preserving extracellular matrix architecture for biological scaffolds.Frontiers in bioengineering and biotechnology · 2026Article
- Engineering vascular grafts from decellularized plants: Advances and challenges.Histology and histopathology · 2025Review
- Microfluidic Design of Ultradeformable Liposomes for Advanced Skin Delivery ofPharmaceutics · 2025Article
- New Rat Model Mimicking Sacrocolpopexy for POP Treatment and Biomaterials Testing via Unilateral Presacral Suspension.International urogynecology journal · 2025Article
- Suspension electrospinning of decellularized extracellular matrix: A new method to preserve bioactivity.Bioactive materials · 2024Article
- OX26-cojugated gangliosilated liposomes to improve the post-ischemic therapeutic effect of CDP-choline.Drug delivery and translational research · 2024Article
- Photo-responsive decellularized small intestine submucosa hydrogels.Advanced functional materials · 2024Article
- The application of small intestinal submucosa in tissue regeneration.Materials today. Bio · 2024Review
- Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy.Bioactive materials · 2024Review
- Periapical lesion-derived decellularized extracellular matrix as a potential solution for regenerative endodontics.Regenerative biomaterials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Structural cardiac lesions are often surgically repaired using prosthetic patches, which can be biological or synthetic. In the current clinical scenario, biological patches derived from the decellularization of a xenogeneic scaffold are gaining more interest as they maintain the natural architecture of the extracellular matrix (ECM) after the removal of the native cells and remnants. Once implanted in the host, these patches can induce tissue regeneration and repair, encouraging angiogenesis, migration, proliferation, and host cell differentiation. Lastly, decellularized xenogeneic patches undergo cell repopulation, thus reducing host immuno-mediated response against the graft and preventing device failure. Porcine small intestinal submucosa (pSIS) showed such properties in alternative clinical scenarios. Specifically, the US FDA approved its use in humans for urogenital procedures such as hernia repair, cystoplasties, ureteral reconstructions, stress incontinence, Peyronie's disease, penile chordee, and even urethral reconstruction for hypospadias and strictures. In addition, it has also been successfully used for skeletal muscle tissue reconstruction in young patients. However, for cardiovascular applications, the results are controversial. In this study, we aimed to validate our decellularization protocol for SIS, which is based on the use of Tergitol 15 S 9, by comparing it to our previous and efficient method (Triton X 100), which is not more available in the market. For both treatments, we evaluated the preservation of the ECM ultrastructure, biomechanical features, biocompatibility, and final bioinductive capabilities. The overall analysis shows that the SIS tissue is macroscopically distinguishable into two regions, one smooth and one wrinkle, equivalent to the ultrastructure and biochemical and proteomic profile. Furthermore, Tergitol 15 S 9 treatment does not modify tissue biomechanics, resulting in comparable to the native one and confirming the superior preservation of the collagen fibers. In summary, the present study showed that the SIS decellularized with Tergitol 15 S 9 guarantees higher performances, compared to the Triton X 100 method, in all the explored fields and for both SIS regions: smooth and wrinkle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.